PROK logo

PROK
ProKidney Corp

1,786
Mkt Cap
$510.31M
Volume
633,761.00
52W High
$7.13
52W Low
$0.54
PE Ratio
-3.21
PROK Fundamentals
Price
$1.75
Prev Close
$1.69
Open
$1.66
50D MA
$1.90
Beta
2.60
Avg. Volume
1.01M
EPS (Annual)
-$0.515
P/B
-0.23
Rev/Employee
$3,865.80
$1,346.04
Loading...
Loading...
News
all
press releases
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
More News
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
ProKidney (PROK) to Release Quarterly Earnings on Monday
ProKidney (NASDAQ:PROK) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-prokidney-corp-stock...
MarketBeat·17d ago
News Placeholder
ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen
Wall Street Zen upgraded ProKidney from a "strong sell" rating to a "sell" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy?
ProKidney (NASDAQ:PROK) Trading 9% Higher - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of ProKidney Corp. (NASDAQ:PROK - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a...
MarketBeat·1mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - Time to Buy?
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - What's Next...
MarketBeat·1mo ago
News Placeholder
Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK
Hennion & Walsh Asset Management Inc. lifted its stake in shares of ProKidney Corp. (NASDAQ:PROK - Free Report) by 63.5% in the 4th quarter, according to its most recent Form 13F filing with the...
MarketBeat·2mo ago
News Placeholder
ProKidney (NASDAQ:PROK) Shares Up 5.9% - Here's Why
ProKidney (NASDAQ:PROK) Trading 5.9% Higher - What's Next...
MarketBeat·2mo ago
<
1
2
...
>

Latest PROK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.